Currently Viewing:
Patient-Centered Oncology Care
Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says
November 17, 2017
Navigators Offer Touch Points on Patients' Cancer Journey
November 18, 2017
Documenting When a Patient Falls Outside a Recommended Pathway
November 20, 2017
Ian Manners: Addressing Financial Toxicity for Patients
November 29, 2017
The Importance of Teamwork in Oncology Care Transitions
November 30, 2017
Dr Brenton Fargnoli Highlights How Practices Can Prepare for Downside Risk
December 15, 2017
Kathleen Lokay: Clinical Pathways Can Prevent Prior Authorization Delays
December 24, 2017
Torrie Fields: Data Collection Takes the Guesswork Out of Care
January 01, 2018
Kathleen Lokay on How Data Generation Informs Clinical Pathways
January 16, 2018
Dr Brenton Fargnoli Discusses the Creation of a Learning Health System
January 25, 2018
Kathleen Lokay on Educating Patients on Treatment Options
January 28, 2018
Dr Brenton Fargnoli Explains How Quality Measurement Benchmarks Drive Action
February 09, 2018
Jason Harris Discusses the Importance of Real-World Evidence
February 11, 2018
Kathleen Lokay: Implementing Value in Clinical Pathways
February 13, 2018
Dr Brenton Fargnoli on Fixing Issues Physicians Have With EHRs
February 18, 2018
Jason Harris: Improving Patient Understanding and Promoting High-Value Care
March 02, 2018
Currently Reading
Dr Thomas Graf on the Impact of New Therapies in Oncology
March 12, 2018
Jason Harris Highlights National Health Council's Recommendations on Real-World Evidence
March 18, 2018
Dr Thomas Graf: How the Impact of Novel Therapies Varies Among Stakeholders
March 22, 2018
Dr Stacey McCullough on the Pharmacist's Role in Patient Education
March 29, 2018
Kathleen Lokay: Incorporating the Latest Research and Supporting Physicians
April 05, 2018
Dr Thomas Graf Discusses the Effect of Novel Therapies on Private Coverage
April 06, 2018
Torrie Fields: Collecting and Using Data Can Better Inform a Patient
April 12, 2018
Dr Stacey McCullough Discusses Teamwork and Collaboration in Oncology
April 13, 2018

Dr Thomas Graf on the Impact of New Therapies in Oncology

Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.


Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses the impact of increases in drug prices on oncology stakeholders.

Trascript

What is the impact of novel therapies on oncology stakeholders?

The whole challenge with healthcare these days is the total cost of care, and these new cancer therapies have really changed the cost paradigm. So, going from drugs that were hundreds or thousands of dollars to drugs that are hundreds of thousands of dollars has an impact on employers, it’s likely to raise the total cost of care, certainly the patient out-of-pocket expense with high deductible plans can be a real factor. But, the biggest impact is really on hospitals and insurance providers because therapies that are administered in inpatient are often included within a DRG, and that cost obviously blows up what the traditional DRG is. For those that are outpatient, it’s an added cost to the insurers, and the ability to understand what those costs are in an appropriately priced product when they’re selling them, (ie passing them on to the ultimate payer). It’s a real revolution in the costs of understanding how to manage this kind of cost in the explosion of new therapies is a real challenge, and figuring that out is gonna be the next few year’s work.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up